Skip to content
Medical Health Aged Care, Science

Advancing melanoma treatment against resistance

Centenary Institute 2 mins read
Study co-lead authors Dr Cindy Hsin-Yi Tseng and Dr Sara Alavi

Research conducted by the Centenary Institute has revealed a promising new approach to tackling melanoma, an aggressive form of skin cancer notorious for its resistance to conventional treatments.

 

Published in the science journal Pigment Cell & Melanoma Research, the study identifies a new ‘dual drug’ strategy that could redefine treatment options for patients facing immune checkpoint blockade resistance, a frequent challenge in melanoma treatment.

 

Immune checkpoint blockade (ICB) therapy, a form of immunotherapy, aids the immune system in identifying and attacking cancer cells by blocking proteins that hinder immune responses. However, overcoming patients' physical resistance to ICB therapy remains a significant obstacle in treating melanoma.

 

The study found that high levels of bromodomain and extra terminal (BET) proteins were linked to poorer survival and less effective ICB responses in people with melanoma. Additionally, in experiments involving mice, a combination of two drugs, BET inhibitor IBET151 and anti-CTLA-4, successfully overcame innate resistance to ICB, suggesting a new and promising treatment option for many melanoma patients.

 

Dr Cindy Hsin-Yi Tseng, co-lead study author and researcher at the Centenary Institute’s Centre for Cancer Innovations said melanoma poses a significant clinical challenge.

 

“About half of all melanoma patients don’t respond to immune checkpoint blockade therapy due to treatment resistance. Even those who initially respond positively may eventually lose that response, impacting their long-term survival,” said Dr Tseng.

 

"Our research not only sheds light on the reasons behind treatment resistance but also proposes a new drug combination for melanoma patients with innate resistance to this type of immunotherapy. This breakthrough brings renewed hope for improved treatments benefitting both patients and clinicians,” she said.

The study was jointly led by Dr Cindy Hsin-Yi Tseng and Dr Sara Alavi of the Centenary Institute’s Centre for Cancer Innovations.

 

Melanoma accounts for approximately 1,300 deaths annually in Australia and is the third most diagnosed cancer in the country.

 

[ENDS]

 


Key Facts:

Publication:

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment

https://onlinelibrary.wiley.com/doi/10.1111/pcmr.13174


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

 

For more information about the Centenary Institute, visit centenary.org.au

 


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: t.crawshaw@centenary.org.au

Media

More from this category

  • Medical Health Aged Care
  • 23/05/2024
  • 11:26
Royal Australian College of GPs

“No patients should miss out”: GPs call for urgent action on payroll tax hit

The Royal Australia College of GPs (RACGP) is calling on all state and territory governments to save the future of general practice care so that no patients miss out. It comes ahead of the College’s annual Practice Owner’s National Conference in Cairns running 24 to 26 May. This year’s conference includes a presentation entitled Empowering Practices Through Payroll Tax: Reflecting, Positioning, and Advancing. Conducted by Senior Associate Ben Ryan and former RACGP Vice President and Queensland Chair, DrBruceWillett, the session focusses on the challenges posed by this payroll tax hit, the achievements of the College so far fighting for a…

  • Medical Health Aged Care
  • 23/05/2024
  • 11:17
Dementia Australia

On this weekend – Brisbane Memory Walk & Jog

The 2024 Brisbane Memory Walk & Jog is upon us, with the much-anticipated event taking place this weekend on Sunday 26 May at Rocks Riverside Park, Seventeen Mile Rocks. Starting at 7.30am, we welcome everyone in the Brisbane community to join fellow participants as they walk, jog or run to help raise money in support of people living with dementia. Special guests, Dementia Australia Ambassador Wally Lewis AM will be in attendance alongside this year’s MC Dementia Australia Ambassador Takaya Honda. Registrations for the Brisbane Memory Walk & Jog are still open and we would love to see as many…

  • Contains:
  • Medical Health Aged Care
  • 23/05/2024
  • 11:14
Dementia Australia

On this weekend – Perth Memory Walk & Jog

The 2024 Perth Memory Walk & Jog is upon us, with the much-anticipated event taking place this weekend on Sunday 26 May at Burswood Park, Burswood. Starting at 7.30am, we welcome everyone in the Perth community to join fellow participants as they walk, jog or run to help raise money in support of people living with dementia. Registrations for the Perth Memory Walk & Jog are still open and we would love to see as many people as possible participate to help raise funds and awareness for such an important cause. Walk or jog with us. We are in this…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.